Evaluation of Ceftaroline Activity versus Daptomycin (DAP) against DAP-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model

被引:23
|
作者
Steed, Molly [1 ]
Vidaillac, Celine [1 ]
Rybak, Michael J. [1 ,2 ]
机构
[1] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI 48201 USA
[2] Wayne State Univ, Sch Med, Detroit, MI 48201 USA
关键词
COMPLICATED SKIN; DOUBLE-BLIND; PHASE-III; CANVAS; VANCOMYCIN-INTERMEDIATE; ANTIMICROBIAL ACTIVITY; SUSCEPTIBILITY; CEPHALOSPORIN; SAFETY; FOSAMIL;
D O I
10.1128/AAC.00347-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The objective of this study was to investigate the potential role of ceftaroline, a new broad-spectrum cephalosporin, as a therapeutic option for the treatment of daptomycin-nonsusceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) infections. Four clinical DNS MRSA strains, R5717, R5563, R5996 (heteroresistant vancomycin-intermediate S. aureus) and R5995 (vancomycin-intermediate S. aureus) were evaluated in a two-compartment hollow-fiber in vitro pharmacokinetic/pharmacodynamic model at a starting inoculum of 10(7) CFU/ml for 96 h. Simulated regimens were ceftaroline at 600 mg every 12 h (q12h) (maximum free-drug concentration [fC(max)], 15.2 mu g/ml; serum half-life [t(1/2)], 2.3 h), daptomycin at 6 mg/kg q24h (fC(max), 7.9 mu g/ml; t(1/2), 8 h), and daptomycin at 10 mg/kg q24h (fC(max), 15.2 mu g/ml; t(1/2), 8 h). Differences in CFU/ml between 24 and 96 h were evaluated by analysis of variance with Tukey's post-hoc test. Bactericidal activity was defined as a >= 3-log(10) CFU/ml decrease in the colony count from the initial inoculum. The ceftaroline MIC values were 0.25, 0.5, 0.5, and 0.5 mu g/ml, and the daptomycin MIC values were 2, 2, 4, and 4 mu g/ml for R5717, R5563, R5996, and R5995, respectively. Ceftaroline displayed sustained bactericidal activity against 3 of the 4 strains at 96 h (R5717, -3.1 log(10) CFU/ml; R5563, -2.5 log(10) CFU/ml; R5996, -5.77 log(10) CFU/ml; R5995, -6.38 log(10) CFU/ml). Regrowth occurred during the daptomycin at 6-mg/kg q24h regimen (4 strains) and the daptomycin at 10-mg/kg q24h regimen (3 strains). At 96 h, ceftaroline was significantly more active, resulting in CFU/ml counts lower than those obtained with daptomycin at 6 mg/kg q24h (4 strains, P <= 0.008) and daptomycin at 10 mg/kg q24 h (3 strains, P <= 0.001). Isolates with increased MIC values for daptomycin (all 4 strains) but not for ceftaroline were recovered. Ceftaroline was effective against the 4 isolates tested and may provide a clinical option for the treatment of DNS MRSA infections.
引用
收藏
页码:3522 / 3526
页数:5
相关论文
共 50 条
  • [31] Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model
    Dandekar, PK
    Tessier, PR
    Williams, P
    Nightingale, CH
    Nicolau, DP
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (03) : 405 - 411
  • [32] In vitro testing of daptomycin plus rifampin against methicillin-resistant Staphylococcus aureus resistant to rifampin
    Khasawneh, FaisalA.
    Ashcraft, Deborah S.
    Pankey, George A.
    SAUDI MEDICAL JOURNAL, 2008, 29 (12) : 1726 - 1729
  • [33] Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations
    Smith, Jordan R.
    Yim, Juwon
    Rice, Seth
    Stamper, Kyle
    Kebriaei, Razie
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (05)
  • [34] Linezolid versus vancomycin in vitro activity against methicillin-resistant Staphylococcus aureus biofilms
    Al-Zehhawi, Perrynaz Ahmed Mahmood
    Jaddoa, Nihad Taha Mohammed
    MICROBIAL PATHOGENESIS, 2025, 201
  • [35] In vitro efficacy of Daptomycin against clinical isolates of Methicillin-resistant Staphylococcus aureus (MRSA)
    Shah, Asim Ali
    Abbasi, Shahid Ahmad
    Ali, Yasir
    Maqbool, Ayesha
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2021, 71 (01) : 338 - 340
  • [36] Pharmacokinetic-Pharmacodynamic Modeling of the In Vitro Activities of Oxazolidinone Antimicrobial Agents against Methicillin-Resistant Staphylococcus aureus
    Schmidt, Stephan
    Sabarinath, Sreedharan Nair
    Barbour, April
    Abbanat, Darren
    Manitpisitkul, Prasarn
    Sha, Sue
    Derendorf, Hartmut
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (12) : 5039 - 5045
  • [37] Antibacterial activity of flavonoids against methicillin-resistant Staphylococcus aureus strains
    Alcaráz, LE
    Blanco, SE
    Puig, ON
    Tomás, F
    Ferretti, FH
    JOURNAL OF THEORETICAL BIOLOGY, 2000, 205 (02) : 231 - 240
  • [38] Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model (vol 57, pg 66, 2013)
    Werth, Brian J.
    Sakoulas, George
    Rose, Warren E.
    Pogliano, Joseph
    Tewhey, Ryan
    Rybak, Michael J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (03) : 1565 - 1565
  • [39] Outcomes of Daptomycin Plus Ceftaroline Versus Alternative Therapy for Persistent Methicillin-resistant Staphylococcus aureus (MRSA) Bacteraemia
    Patel, Darshan
    Brown, Matthew L.
    Edwards, Seth
    Oster, Robert A.
    Stripling, Joshua
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 61 (03)
  • [40] Activity of Vancomycin and Piperacillin-Tazobactam in combination against Methicillin-Resistant Staphylococcus aureus and VAN-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic infection model.
    Dilworth, Tom
    Leonard, Steve
    Mercier, Renee
    PHARMACOTHERAPY, 2013, 33 (10): : E215 - E216